home / stock / dest / dest quote
Last: | $ |
---|---|
Change Percent: | 8.05% |
Open: | $0.3703 |
Close: | $0.3999 |
High: | $0.418 |
Low: | $0.33 |
Volume: | 3,115,794 |
Last Trade Date Time: | 10/15/2019 07:26:50 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $0.3703 | $0.3999 | $0.418 | $0.33 | 3,115,794 | 10-15-2019 |
$ | $0.3726 | $0.378 | $0.3899 | $0.371 | 479,001 | 10-11-2019 |
$ | $0.4084 | $0.384 | $0.4095 | $0.366 | 1,216,469 | 10-10-2019 |
$ | $0.396 | $0.413 | $0.4199 | $0.38 | 1,029,815 | 10-09-2019 |
$ | $0.4134 | $0.3949 | $0.42 | $0.3836 | 590,844 | 10-08-2019 |
$ | $0.4205 | $0.413 | $0.43 | $0.384 | 820,888 | 10-07-2019 |
$ | $0.438 | $0.4224 | $0.438 | $0.41 | 1,076,273 | 10-04-2019 |
$ | $0.45 | $0.43 | $0.45 | $0.405 | 2,059,801 | 10-03-2019 |
$ | $0.415 | $0.455 | $0.475 | $0.3529 | 2,716,738 | 10-02-2019 |
$ | $0.4799 | $0.400144 | $0.4799 | $0.40 | 2,505,952 | 10-01-2019 |
$ | $0.40 | $0.4149 | $0.45 | $0.40 | 1,687,271 | 09-30-2019 |
$ | $0.56 | $0.40 | $0.5699 | $0.33 | 2,968,776 | 09-27-2019 |
$ | $0.61 | $0.5292 | $0.7714 | $0.511 | 973,027 | 09-26-2019 |
$ | $0.51 | $0.62 | $0.6489 | $0.508 | 287,451 | 09-25-2019 |
$ | $0.5542 | $0.53 | $0.56 | $0.5011 | 82,748 | 09-24-2019 |
$ | $0.54 | $0.5542 | $0.5678 | $0.5251 | 71,531 | 09-23-2019 |
$ | $0.565 | $0.5317 | $0.60 | $0.5268 | 462,077 | 09-20-2019 |
$ | $0.6116 | $0.5836 | $0.6116 | $0.565 | 154,575 | 09-19-2019 |
$ | $0.60 | $0.5918 | $0.659852 | $0.55 | 385,295 | 09-18-2019 |
$ | $0.6718 | $0.683 | $0.7195 | $0.6531 | 237,313 | 09-17-2019 |
News, Short Squeeze, Breakout and More Instantly...
Destination Maternity Corporation Company Name:
DEST Stock Symbol:
NASDAQ Market:
Destination Maternity Corporation Website:
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than ...
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Thomas Warner from Proactive after releasing the clinical-stage biotechnology company's full year results for 2022. Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, ...
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal. Love explains what makes the platform so promis...